Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Reduced amplitude of mismatch negativity (MMN) is one of the more promising biological markers of schizophrenia. This finding holds true in both early and chronic phases of the disorder, and is compatible with the glutamatergic dysfunction hypothesis. To further establish MMN as a biomarker of aberrant glutamatergic neurotransmission, an exploration for an association with blood levels of glutamatergic amino acids is an important next step. Despite a large body of work investigating MMN in schizophrenia, no previous studies have undertaken this endeavor. Nineteen patients with first-episode psychosis (FEP), 21 ultra-high risk individuals (UHR), and 16 healthy controls (HC) participated in the study. The MMNs in response to duration change (dMMN) and frequency change (fMMN) were measured. The fasting plasma levels of glutamate, glutamine, glycine, D-serine, and L-serine were measured. dMMN amplitudes were significantly reduced in FEP and UHR, compared to HC. The plasma levels of glutamate of FEP were significantly higher than those of HC. Higher plasma levels of glutamate were associated with smaller dMMN amplitudes in the FEP and HC groups. These findings are compatible with the hypothesis that MMN is a useful biological marker of aberrant glutamatergic neurotransmission in the early stages of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Insel, T. R., & Cuthbert, B. N. (2015) · Science · doi:10.1126/science.aab2358 · Cited by 840
Mismatch negativity in schizophrenia: a meta-analysis
Umbricht, D., & Krljes, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.002 · Cited by 742
MATSUOKA, K., UNO, M., KASAI, K., KOYAMA, K., & KIM, Y. (2006) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2006.01510.x · Cited by 491
Self-citationErickson, M. A., Ruffle, A., & Gold, J. M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.025 · Cited by 426
Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients
Light, G. A., & Braff, D. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.127 · Cited by 407
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322
Cited by
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Mismatch negativity (MMN) as a tool for translational investigations into early psychosis: A review
Tada, M., Kirihara, K., Mizutani, S., Uka, T., Kunii, N., Koshiyama, D., Fujioka, M., Usui, K., Nagai, T., Araki, T., et al. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.02.009 · Cited by 74
Self-citationReduced Auditory Mismatch Negativity Reflects Impaired Deviance Detection in Schizophrenia
Koshiyama, D., Kirihara, K., Tada, M., Nagai, T., Fujioka, M., Usui, K., Araki, T., & Kasai, K. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa006 · Cited by 63
Self-citationBraeutigam, S., Dima, D., Frangou, S., & James, A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.048 · Cited by 20
Metadata
- Authors
- Nagai, T., Kirihara, K., Tada, M., Koshiyama, D., Koike, S., Suga, M., Araki, T., Hashimoto, K., & Kasai, K.
- Venue
- Scientific Reports
- Published
- 2017-05-23
- Volume
- 7
- Issue
- 1
- Pages
- 2258-2258
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2616413210
- Cited by
- 62
- References
- 15
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis. https://app.cochat.ai/papers/10.1038/s41598-017-02267-1
- The paper
- Nagai, T., Kirihara, K., Tada, M., Koshiyama, D., Koike, S., Suga, M., Araki, T., Hashimoto, K., & Kasai, K. (2017). Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis. Scientific Reports. https://doi.org/10.1038/s41598-017-02267-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.